About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
SOHO Brazil
SOHO Brazil 2023
SOHO Brazil 2022
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
SOHO Brazil 2022: When Low-Risk MDS Behaves Badly
By
SOHO Brazil 2022
FEATURING
Amer Zeidan
,
Phillip Scheinberg
By
SOHO Brazil 2022
FEATURING
Amer Zeidan
,
Phillip Scheinberg
3 views
August 31, 2022
0 Comments
Login to view comments.
Click here to Login
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Featured Video
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
SOHO Brazil 2022
25:36
SOHO Brazil 2022
SOHO Brazil 2022: Are All MZLs the Same? What Do We Know About Subty…
Feat.
I. Lossos,
P. Scheinberg
27:08
SOHO Brazil 2022
Are We Curing Some Mantle Cell Lymphomas?
Feat.
J. Chavez,
A. Alencar
23:08
SOHO Brazil 2022
SOHO Brazil 2022 on Bispecifics in Follicular Lymphoma: A “Mini-Revo…
Feat.
J. Chavez,
A. Alencar
24:15
SOHO Brazil 2022
SOHO Brazil 2022 on CPIs in Hodgkin Lymphoma: Recent Progress
Feat.
P. Armand,
A. Alencar
24:28
SOHO Brazil 2022
SOHO Brazil 2022 on DLBCL: Finally Breaking the Back of R-CHOP?
Feat.
C. Moskowitz,
A. Alencar
23:04
SOHO Brazil 2022
SOHO Brazil 2022 on 1st Relapse in DLBCL: Induction Chemo & Auto…
Feat.
M. Bishop,
P. Scheinberg
26:04
SOHO Brazil 2022
SOHO Brazil 2022 on Targeted Therapy in Indolent Lymphomas: The Role…
Feat.
I. Lossos,
P. Scheinberg
32:17
SOHO Brazil 2022
SOHO Brazil 2022 on Waldenstrom’s Macroglobulinemia: The More Diffic…
Feat.
S. Treon,
P. Scheinberg
27:03
SOHO Brazil 2022
SOHO Brazil 2022: Who Is a Candidate for CAR-T in DLBCL? The Window …
Feat.
M. Bishop,
A. Alencar,
P. Scheinberg
36:30
SOHO Brazil 2022
SOHO Brazil 2022 Discussion: What Are the Options in Primary CNS Lym…
Feat.
J. Rubenstein,
A. Alencar
23:00
SOHO Brazil 2022
SOHO Brazil 2022 Discussion on MM: Will Sequencing Be Important With…
Feat.
M. Bishop,
N. Korde,
E. Manasanch,
P. Scheinberg
26:42
SOHO Brazil 2022
SOHO Brazil 2022: When Low-Risk MDS Behaves Badly
Feat.
A. Zeidan,
P. Scheinberg
15:29
SOHO Brazil 2022
SOHO Brazil 2022 on CAR-T in Refractory MM: When Is the Precise Mome…
Feat.
M. Bishop,
P. Scheinberg
16:24
SOHO Brazil 2022
SOHO Brazil 2022 Latest News on Third Generation Imune Modulating Ag…
Feat.
E. Manasanch,
P. Scheinberg
29:02
SOHO Brazil 2022
SOHO Brazil 2022: My Low-Risk MDS Patient With Ring Sideroblasts Is …
Feat.
H. Carraway,
P. Scheinberg
20:09
SOHO Brazil 2022
SOHO Brazil 2022: How Is the Great Barrier of Highly-Resistant Myelo…
Feat.
A. Zeidan,
P. Scheinberg
27:44
SOHO Brazil 2022
SOHO Brazil 2022 on MDS: Get to Know the IPSS-M & Other Molecula…
Feat.
M. Sekeres,
P. Scheinberg
29:49
SOHO Brazil 2022
SOHO Brazil 2022: Bringing AML Approaches to High-Risk MDS - Is It W…
Feat.
A. Zeidan,
P. Scheinberg
23:10
SOHO Brazil 2022
SOHO Brazil 2022: All You Need to Know (Until Now) About Targeted Th…
Feat.
K. Pratz,
P. Scheinberg
32:48
SOHO Brazil 2022
SOHO Brazil 2022 on Refractory ALL: What Is the Precise Time to Indi…
Feat.
M. Bishop,
P. Scheinberg
16:45
SOHO Brazil 2022
SOHO Brazil 2022 on CLL: The PI3K Inhibitors, the "Not-So-New K…
Feat.
N. Jain,
P. Scheinberg
20:09
SOHO Brazil 2022
SOHO Brazil 2022 on CLL: The BTK Inhibitors That Continue to “Heat-U…
Feat.
N. Jain,
P. Scheinberg
22:54
SOHO Brazil 2022
SOHO Brazil 2022 on Ph+ ALL: Is the Combination With TKIs Curing Pat…
Feat.
J. Ribera,
P. Scheinberg
20:04
SOHO Brazil 2022
SOHO Brazil 2022 on High-Risk AML: Is Conventional Chemo Still the B…
Feat.
D. Pollyea,
P. Scheinberg
20:23
SOHO Brazil 2022
SOHO Brazil 2022 on Doublets & Triplets With Venetoclax in AML: …
Feat.
D. Pollyea,
P. Scheinberg
26:48
SOHO Brazil 2022
SOHO Brazil 2022 on CLL: Do BTKi + BCL2 Inhibitors Need a Partner?
Feat.
N. Jain,
P. Scheinberg
25:29
SOHO Brazil 2022
SOHO Brazil 2022: Can Someone Be Destined to Develop AML? Understand…
Feat.
L. Godley,
P. Scheinberg